S'abonner

Resurgence of scarlet fever in England, 2014–16: a population-based surveillance study - 02/02/18

Doi : 10.1016/S1473-3099(17)30693-X 
Theresa Lamagni, PhD a, b, , Rebecca Guy, BSc a, Meera Chand, MBBS a, c, d, Katherine L Henderson, PhD a, Victoria Chalker, PhD a, b, James Lewis, BSc e, Vanessa Saliba, MD a, Alex J Elliot, PhD a, Gillian E Smith, MBBS a, Stephen Rushton, ProfPhD f, Elizabeth A Sheridan, MBBS a, Mary Ramsay, MBBS a, Alan P Johnson, PhD a, b
a National Infection Service, Public Health England, London, UK 
b National Institute for Health Research Health Protection Research Unit in Healthcare-Associated Infection & Antimicrobial Resistance, Imperial College, London, UK 
c Department of Infectious Diseases, Guy’s & St Thomas’ NHS Foundation Trust, London, UK 
d National Institute for Health Research Health Protection Research Unit in Respiratory Infections, Imperial College, London, UK 
e Emergency Response Department Science and Technology, Health Protection Directorate, Public Health England, Porton Down, Salisbury, UK 
f School of Biology, Newcastle University, Newcastle, UK 

* Correspondence to: Dr Theresa Lamagni, National Infection Service, Public Health England, London NW9 5EQ, UK Correspondence to: Dr Theresa Lamagni, National Infection Service Public Health England London NW9 5EQ UK

Summary

Background

After decades of decreasing scarlet fever incidence, a dramatic increase was seen in England beginning in 2014. Investigations were launched to assess clinical and epidemiological patterns and identify potential causes.

Methods

In this population-based surveillance study, we analysed statutory scarlet fever notifications held by Public Health England from 1911 to 2016 in England and Wales to identify periods of sudden escalation of scarlet fever. Characteristics of cases and outbreaks in England including frequency of complications and hospital admissions were assessed and compared with the pre-upsurge period. Isolates from throat swabs were obtained and were emm typed.

Findings

Data were retrieved for our analysis between Jan 1, 1911, and Dec 31, 2016. Population rates of scarlet fever increased by a factor of three between 2013 and 2014 from 8·2 to 27·2 per 100 000 (rate ratio [RR] 3·34, 95% CI 3·23–3·45; p<0·0001); further increases were observed in 2015 (30·6 per 100 000) and in 2016 (33·2 per 100 000), which reached the highest number of cases (19 206) and rate of scarlet fever notifcation since 1967. The median age of cases in 2014 was 4 years (IQR 3–7) with an incidence of 186 per 100 000 children under age 10 years. All parts of England saw an increase in incidence, with 620 outbreaks reported in 2016. Hospital admissions for scarlet fever increased by 97% between 2013 and 2016; one in 40 cases were admitted for management of the condition or potential complications. Analysis of strains (n=303) identified a diversity of emm types with emm3 (43%), emm12 (15%), emm1 (11%), and emm4 (9%) being the most common. Longitudinal analysis identified 4-yearly periodicity in population incidence of scarlet fever but of consistently lower magnitude than the current escalation.

Interpretation

England is experiencing an unprecedented rise in scarlet fever with the highest incidence for nearly 50 years. Reasons for this escalation are unclear and identifying these remains a public health priority.

Funding

None.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 18 - N° 2

P. 180-187 - février 2018 Retour au numéro
Article précédent Article précédent
  • Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1?+?1) compared with two primary doses and a booster (2?+?1) in UK infants: a multicentre, parallel group randomised controlled trial
  • David Goldblatt, Jo Southern, Nick J Andrews, Polly Burbidge, Jo Partington, Lucy Roalfe, Marta Valente Pinto, Vasilli Thalasselis, Emma Plested, Hayley Richardson, Matthew D Snape, Elizabeth Miller
| Article suivant Article suivant
  • Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study
  • Lucas E Hermans, Michelle Moorhouse, Sergio Carmona, Diederick E Grobbee, L Marije Hofstra, Douglas D Richman, Hugo A Tempelman, Willem D F Venter, Annemarie M J Wensing

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.